- Dimerix buys a kidney injury drug; Arpeggio appears to be winding downPlus, news about Takeda, Novartis and Regenxbio. 🤝 Mission sells kidney injury drug to Dimerix: Dimerix will pay $5 million upfront for Mission’s Phase 2-ready candidate for acute kidney injury,…Endpoints · 7d ago↗ source
- Updated: BlossomHill and Latigo join flourishing IPO queue with cancer, pain drugsLast summer, zero biotechs made it onto the public markets as the industry weathered a seven-month dry spell for initial share sales. This time around, it's a summer IPO party as sixEndpoints · 7d ago↗ source
- BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fieldsAnother biotech is squeezing into the crowded IPO waiting room just in time for the weekend. BlossomHill Therapeutics, a San Diego-based oncology outfit focused on small molecules, has filed paperw…